Triplet chemotherapy in combination with anti-EGFR agents for the treatment of metastatic colorectal cancer: current evidence, advances, and future perspectives

With over 935,000 deaths estimated to occur annually, colorectal cancer (CRC) is the second leading cause of cancer-related mortality [1]. Each year, ∼1.9 million cases of CRC occur worldwide, including ∼322,000 cases in North America and Western Europe [1], with metastatic disease developing in nearly 40% [2].

Source: Cancer Treatment Reviews - November 10, 2021 Category: Cancer & Oncology Authors: Gunnar Folprecht, Erika Martinelli, Thibault Mazard, Dominik P. Modest, Akihito Tsuji, Regina Esser, Chiara Cremolini, Alfredo Falcone Source Type: research